Health & Fitness

Pfizer, BioNTech Submit Vaccine Trial Data For Kids Ages 5-11

Pfizer said the trial, which tested the COVID-19 vaccine in more than 2,200 kids, yielded "positive topline results."

Megan VerHelst's profile picture
Megan VerHelst, Patch StaffVerified Patch Staff Badge
Pfizer and BioNTech on Tuesday submitted data to the U.S. Food and Drug Administration on a vaccine trial for kids ages 5-11. The companies are expected to request emergency use authorization for the age group in the coming weeks.
Pfizer and BioNTech on Tuesday submitted data to the U.S. Food and Drug Administration on a vaccine trial for kids ages 5-11. The companies are expected to request emergency use authorization for the age group in the coming weeks. (Eduardo Munoz/Pool Photo via AP, File)

WASHINGTON, DC — Young children are a step closer to eligibility for a COVID-19 shot after Pfizer and German partner BioNTech submitted data on its latest vaccine trial to the U.S. Food and Drug Administration this week.

The trial, which tested Pfizer's COVID-19 vaccine in more than 2,200 kids between the ages of 5 and 11, yielded “positive topline results,” the companies said on Tuesday. It also "demonstrated a favorable safety profile" and “elicited robust neutralizing antibody responses using a two-dose regimen," according to The Washington Post.

Pfizer is expected to formally request emergency use authorization to administer the vaccine to young children in the coming weeks.

Find out what's happening in Across Americafor free with the latest updates from Patch.

Read more via The Washington Post

Get more local news delivered straight to your inbox. Sign up for free Patch newsletters and alerts.

More from Across America